News

CEO, Anders Hultman, Commenting on FDA delay due to Covid-19

Jan 20, 2021

This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA delay in an interview with Redeye.

Meet us at WHX Labs Dubai 10-13 February

We will be co-exhibiting together with our partner concile at Booth SA.A55. Come by our booth and learn more about our products and how quantitative point-of-care testing can be used to provide accurate and rapid results.

read more

Strategy update: IDL Diagnostics

A strategy update with IDL Diagnostics was held on November 27th at Redeye, where CEO Anders Hultman and the management team presented recent achievements, spotlighted key initiatives, and discussed future opportunities looking toward 2026 and beyond. After their...

read more